Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
SGMO Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Sangamo Therapeutics, Inc.NASDAQ: SGMO
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $1.44M fell 77.6% year over year, behind the -45.8% change in trailing-twelve-month revenue. Sequentially, it fell 89.9% from the prior quarter. Over 3 fiscal years it compounded at -29.2% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 1 analysts of $67.6M (+70.9%) for the fiscal year ending Dec 2026, a step up from the -31.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.44M-89.9% QoQ
- Last fiscal yearDec 2025
- $39.55M-31.6% YoY
- LTMMar 2026
- $34.56M-45.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -77.6% | -19.9% | +57.7 pp |
| 1 year | -31.6% | +70.9% | +102.5 pp |
| 3-year CAGR | -29.2% | +88.3% | +117.5 pp |
| 5-year CAGR | +68.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 39.55M USD
- Year-over-year change
- -31.6%
- 4-year CAGR
- -22.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.55M | -31.6% |
| FY2024 | 2024-12-31 | 57.8M | -67.2% |
| FY2023 | 2023-12-31 | 176.23M | +58.3% |
| FY2022 | 2022-12-31 | 111.3M | +0.5% |
| FY2021 | 2021-12-31 | 110.7M | — |
Revenue vs competitors
How SGMO compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -45.8% is the 7th highest of 10, against a peer median of -12.4%.
- Over three fiscal years its annual growth of -29.2% compares with a peer median of -20.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $78.09M USD | +56.8% | -20.2% | |
| LTM Mar 2026 | $55.87M USD | +52.3% | — | |
| LTM Mar 2026 | $34.86M USD | -12.4% | +5.0% | |
| LTM Mar 2026 | $34.56M USD | -45.8% | -29.2% | |
| LTM Mar 2026 | $28.91M USD | +8.1% | -31.9% | |
| LTM Mar 2026 | $3.17M USD | +164.1% | — | |
| LTM Mar 2026 | $2.96M USD | -37.1% | -3.8% | |
| FY2025 | €2.79M EUR | -77.9% | -63.6% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $1.95M USD | -49.3% | +61.8% |
| LTM Mar 2026 | $1.78M USD | — | -32.4% | |
| LTM Mar 2026 | CHF 0 CHF | -100.0% | — | |
| Peer median (excluding SGMO) | — | -12.4% | -20.2% | |
Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 110.7M | 111.3M | 176.23M | 57.8M | 39.55M |
| Cost of Revenue | 0 | 12.11M | 0 | 0 | 7.6M |
| Gross Profit | 110.7M | 99.19M | 176.23M | 57.8M | 31.95M |
| Gross Margin | 100.0% | 89.1% | 100.0% | 100.0% | 80.8% |
| Research & Development | 230.82M | 249.9M | 234.06M | 111.52M | 112.67M |
| Selling, General & Admin | 63.22M | 62.68M | 61.17M | 44.73M | 34.89M |
| Operating Expenses | 294.04M | 300.47M | 450.24M | 161.77M | 139.95M |
| Depreciation & Amortization | 17.64M | 12.11M | 22.19M | 9.36M | 7.6M |
| EBITDA | (160.35M) | (179.74M) | (96.8M) | (89.09M) | (115.9M) |
| EBITDA Margin | -144.9% | -161.5% | -54.9% | -154.1% | -293.0% |
| Operating Income | (183.34M) | (201.28M) | (274.01M) | (103.97M) | (108M) |
| Operating Margin | -165.6% | -180.8% | -155.5% | -179.9% | -273.1% |
| Interest Income | 5.35M | 9.43M | 11.1M | 5.86M | 1.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.35M | 9.43M | 11.1M | 5.86M | (15.5M) |
| Income Before Tax | (177.99M) | (191.85M) | (262.9M) | (98.11M) | (123.5M) |
| Pre-Tax Margin | -160.8% | -172.4% | -149.2% | -169.7% | -312.2% |
| Income Tax Expense | 306K | 429K | (5.07M) | (167K) | (568K) |
| Net Income | (178.29M) | (192.28M) | (257.83M) | (97.94M) | (122.93M) |
| Net Margin | -161.1% | -172.8% | -146.3% | -169.4% | -310.8% |
| EPS (Basic) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| EPS (Diluted) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| Weighted Avg Shares | 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
| Weighted Avg Shares (Diluted) | 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
Intrinsic Alpha fair value
Locked
Current Price
$0.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.